Dupixent Approval History
- FDA approved: Yes (First approved March 28th, 2017)
- Brand name: Dupixent
- Generic name: dupilumab
- Dosage form: Injection
- Company: Sanofi and Regeneron Pharmaceuticals, Inc.
- Treatment for: Atopic Dermatitis
Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis.
The FDA approval of Dupixent was based on the results of the LIBERTY AD Clinical Program which included three randomized Phase 3 pivotal trials of 2,119 adult patients with inadequately controlled atopic dermatitis. The SOLO 1 and SOLO 2 trials examined Dupixent as monotherapy, and the CHRONOS trial examined treatment with both Dupixent and topical corticosteroids. In all trials, Dupixent significantly improved measures of skin clearing, intensity, and severity of disease at 16 weeks compared to placebo.
Dupixent is self-administered via subcutaneous injection every other week after an initial loading dose. Common side effects include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye.
Development History and FDA Approval Process for Dupixent
|Mar 28, 2017|| FDA Approves Dupixent (dupilumab) for Eczema|
|Mar 4, 2017||Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent (dupilumab) in Moderate-to-Severe Atopic Dermatitis|
|Oct 1, 2016||Sanofi and Regeneron Announce Positive Dupixent (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine|
|Sep 26, 2016||Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA|
|Jun 6, 2016||Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients|
|Apr 1, 2016||Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Two Phase 3 Trials in Inadequately Controlled Moderate-To-Severe Atopic Dermatitis Patients|
|Feb 2, 2016||Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data|
|May 18, 2015||Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma|
|Nov 20, 2014||Sanofi And Regeneron Announce That Dupilumab Has Received FDA Breakthrough Therapy Designation In Atopic Dermatitis|
|Nov 11, 2014||Sanofi And Regeneron Announce Positive Results From Phase 2b Study of Dupilumab|
|Oct 20, 2014||Sanofi And Regeneron Announce Start Of Phase 3 Study Of Dupilumab in Patients With Atopic Dermatitis|
|Sep 30, 2014||Sanofi and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps|
|Jul 9, 2014||Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab for Atopic Dermatitis|
|May 21, 2013||Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma|
|Mar 4, 2013||Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.